Best VK2735 Alternatives: The Closest Options You Can Actually Get in 2026

How we make money: some links here are affiliate links, and we may earn a commission if you use them. Our rankings come from verified FDA status, mechanism match, clinical evidence, price transparency, and fit — not commission. This page is education, not medical advice. A licensed clinician decides whether any medication is right for you.

If you’re hunting for the best VK2735 alternatives, here’s the part most pages bury: you can’t actually buy VK2735. Not from a pharmacy. Not from a telehealth clinic. Not legally, anywhere. It’s still an experimental drug working its way through clinical trials, and even on an optimistic timeline it’s roughly two years from a possible launch — if it gets approved at all.

So the real question isn’t “where do I get VK2735.” It’s “what can I get right now that’s closest?” The honest answer is shorter than you’d think: for most people, the closest available option is Zepbound (tirzepatide) (sponsored affiliate link, opens in a new tab), because it works on the exact same two hormones VK2735 targets — and it’s FDA-approved and shipping today. Prefer a pill over a weekly shot? Foundayo or the Wegovy pill are your best bets. If money was the reason you started looking at experimental drugs, there’s a lower-cost compounded route too — but it comes with real tradeoffs, and we’ll lay those out honestly.

Below, we’ll show you exactly which option fits your situation, what each one really costs, how close it actually is to VK2735, and the one “alternative” you should walk away from.

Quick answer: which VK2735 alternative fits you?

There’s no single “best” VK2735 alternative — it depends on three things: do you want a pill or a shot, do you need an FDA-approved drug or are you open to a compounded option, and what’s your budget? Here’s the fast version, then the proof.

Can you actually buy VK2735 right now?

No. VK2735 is an investigational drug, not an available prescription. It’s made by Viking Therapeutics, and as of 2026 the FDA has not approved it for any use, it isn’t sold through any pharmacy, and there’s no lawful routine way to have it compounded. A market launch would still require positive late-stage results, an FDA submission, a full FDA review, and approval — so the often-quoted “2028” is an estimate, not a promised date.

What VK2735 is — and why everyone’s talking about it

VK2735 is a dual GLP-1/GIP agonist. In plain English: it switches on two gut hormones at once — GLP-1 and GIP — that control hunger, fullness, and how your body handles food. That “two switches instead of one” design is exactly why people compare it to tirzepatide (the drug in Zepbound and Mounjaro), which works the same way.

The excitement is understandable. In its mid-stage VENTURE trial, the injectable version produced an average weight loss of up to 14.7% in just 13 weeks — fast numbers that lit up headlines. The pill version also posted positive mid-stage results. On paper, it looks like a heavy hitter.

But those are short, mid-stage results — not the large, long-term, finished data the FDA requires to approve a drug. Here is exactly where VK2735 stands:

Because these are 78-week studies, results read out over time — and even a strong readout only starts the approval process. VK2735 was never “pulled” or “restricted” — it simply hasn’t finished the approval process. There’s no back door, no shortage loophole, and no compounded version — it’s just not done yet.

What that means for you: if your goal is to lose weight this year, waiting on VK2735 means waiting years. The good news is that the thing that makes VK2735 exciting — that dual-hormone mechanism — already exists in a drug you can get today.

Why you should skip the “VK2735” being sold online

Anything sold online as “VK2735” is an unregulated research chemical, not a real medication — and it’s a genuine safety risk. Because VK2735 isn’t approved or commercially made, products labeled “VK2735” on peptide or “research-only” websites have no verified identity, purity, or dose, and the FDA has repeatedly warned that unapproved GLP-1 products like these skip the review for safety, effectiveness, and quality that real medicines go through.

The harm isn’t theoretical. The FDA says it has received reports of adverse events — some requiring hospitalization — tied to dosing errors with compounded injectable semaglutide, including cases where people gave themselves as much as 20 times the intended dose. It has also flagged fraudulent products carrying fake pharmacy names on the label.

Use this red-flag checklist. Walk away from any site that:

• says “research use only” or “not for human consumption,”
• sells without a prescription,
• won’t name a licensed pharmacy or a real prescriber,
• markets VK2735 as a “generic,” or
• implies it’s the same as an FDA-approved GLP-1.

“Research use only” labeling exists so the seller dodges responsibility — it’s a legal shield, not a quality promise.

The VK2735 Alternative Readiness Matrix

This table separates “closest scientifically” from “available legally” — because the best alternative isn’t the drug with the flashiest headline, it’s the one a qualified clinician can actually prescribe you now.

All rows verified June 16, 2026. Prices change often — confirm current numbers before you commit.

Quick read of the top three:

• Zepbound — the closest match. FDA-approved. Weekly shot. The only approved drug that flips the same two hormone switches VK2735 does.
• Foundayo — the best pill. FDA-approved, once-daily, and the only weight-loss pill you can take any time of day with no food or water rules.
• Wegovy pill — the semaglutide pill. FDA-approved oral semaglutide. Best if you specifically want the Wegovy/semaglutide route in pill form.

What’s the closest thing to VK2735 you can get?

The closest available medication to VK2735 is Zepbound (tirzepatide) (sponsored affiliate link, opens in a new tab). Both are dual GLP-1/GIP agonists — the same two-hormone class — but Zepbound is FDA-approved and on the market, while VK2735 is still experimental. They are not the same drug, and no head-to-head study has compared them in patients.

VK2735 vs Zepbound — the honest comparison

Here’s the helpful way to think about the whole category. Single-hormone GLP-1 drugs (semaglutide/Wegovy) land around 15% average weight loss. Dual-hormone drugs like tirzepatide push that to roughly 22%. The newest triple-hormone drugs in trials reach nearly 28–30%. VK2735 is a dual-hormone drug — so it sits in the same tier as tirzepatide, not above it. That’s not a knock on VK2735; it’s just where the science places it. And tirzepatide is the one in that tier you can actually get.

In its large Phase 3 SURMOUNT-1 trial, tirzepatide produced an average weight loss of about 20.9% at the top dose over 72 weeks — and up to roughly 22.5% in the analysis that measures people who stayed fully on treatment. That’s the strongest published weight-loss result of any FDA-approved obesity medicine to date, now closely matched by the new high-dose Wegovy (about 20.7%).

One caution: resist stacking VK2735’s 14.7% directly against Zepbound’s 20.9%. VK2735’s result came over 13 weeks; Zepbound’s came over 72 weeks — different doses, trials, and lengths. Comparing them straight across is like comparing a sprint time to a marathon time.

The one honest downside — and who should skip Zepbound

Here’s the straight talk: Zepbound is a weekly injection, not a pill. If the whole reason you searched VK2735 was “I want a powerful pill,” then Zepbound is not your pick — jump to the oral options below, where Foundayo is the better fit.

But for most people drawn to VK2735, the appeal was the dual-hormone strength, not the format. And because tirzepatide is given as a steady weekly dose under a clinician’s care, you get the most proven, highest-results option available.

Best oral VK2735 alternative if you don’t want needles

If you want a pill, the best VK2735 alternatives are Foundayo (orforglipron) or the Wegovy pill (oral semaglutide). Both are FDA-approved GLP-1 pills you can get now. One honest note up front: neither is a dual GLP-1/GIP agonist like VK2735 — they work on the single GLP-1 pathway — so they’re a convenience match more than a mechanism match.

Foundayo (orforglipron) — the best no-needle option

Foundayo is the newest of the bunch, FDA-approved in April 2026 for adults with obesity (or overweight with a weight-related condition). It’s a once-daily pill, and it has a real-world perk other oral GLP-1 weight-loss pills don’t: you can take it any time of day, with no food or water restrictions. That matters more than it sounds — oral semaglutide has to be taken first thing in the morning on an empty stomach, then you wait 30 minutes before eating or drinking.

In its Phase 3 program, people on the highest dose lost an average of about 27 pounds (roughly 11–12% of body weight) over 72 weeks. Self-pay pricing starts at $149/month for the lowest dose, with higher doses priced higher.

Wegovy pill (oral semaglutide) — the semaglutide route

The Wegovy pill is FDA-approved oral semaglutide, approved in December 2025. In its OASIS 4 trial, the once-daily 25 mg pill produced about 13.6% to 16.6% average weight loss over 64 weeks, depending on the analysis, and about one in three people lost 20% or more. Like Foundayo, it’s a once-daily GLP-1 (not a dual agonist), and self-pay pricing starts around $149/month. Because oral semaglutide has its own morning timing and absorption rules, treat it as a clinician-guided choice, not just “the shot in pill form.”

Foundayo vs Wegovy pill — at a glance

What do VK2735 alternatives cost without insurance?

The lowest visible self-pay starting prices are about $149/month for the FDA-approved pills (Foundayo and the Wegovy pill) and about $299/month for the lowest-dose Zepbound self-pay program. But the sticker price isn’t the full story — your real monthly total can include a telehealth membership, a visit fee, lab work, and refill-timing rules that change what you pay. Always confirm current pricing before you commit, because manufacturer and telehealth terms shift often.

Prices above reflect what we verified on June 16, 2026, from the manufacturers’ and providers’ own pages. Re-check before relying on them — savings offers expire and reset.

The part nobody itemizes is your full monthly cost: medication + any membership or program fee + any visit fee + labs, if ordered + refill timing. A provider that’s cheap on the medicine but stacks fees can cost more than one with a clean, all-in price.

Before you assume cash-pay is your only path, find out whether insurance will cover it — it’s free to check, and it’s the single biggest lever on your cost. Ro’s free Insurance Coverage Checker gives you a coverage report in minutes; if you become a Ro patient and your plan requires prior authorization, Ro says its insurance concierge works to get it approved.

Is compounded tirzepatide or semaglutide a VK2735 alternative?

Compounded GLP-1 products are not FDA-approved finished medicines, and they should not be treated as the same as Zepbound, Wegovy, Foundayo, or any future approved VK2735. “Compounded” means a licensed pharmacy custom-mixes a drug for an individual patient. These can be a lower-cost route through some telehealth programs, but the legal ground shifted hard in 2026, and you should understand the tradeoffs before choosing this path.

The upside: compounded tirzepatide and semaglutide are often the cheapest supervised option — commonly advertised between roughly $99 and $250 a month — prescribed by a licensed clinician and dispensed by a licensed pharmacy.

The honest tradeoffs you need to know:

• They’re not FDA-approved. The FDA reviews and approves brand-name drugs; it does not review individual compounded products for safety, effectiveness, or quality.
• The legal situation has tightened. After the FDA declared the tirzepatide and semaglutide shortages resolved (in late 2024 and early 2025), routine compounding of what the FDA calls “essentially a copy” of these drugs became restricted. The FDA has also proposed barring large-scale compounding of these drugs, and court challenges have not succeeded so far.
• Quality depends entirely on the source. A program that uses a licensed, accredited U.S. pharmacy with a real prescriber and ongoing follow-up is a completely different thing from a random website.

A few quick rules on language: a compounded product is not “the same active ingredient as” or “a generic version of” Zepbound or Wegovy, and there’s no such thing as “FDA-approved compounded semaglutide.”

Who this is for: budget-limited readers who can’t access brand options, who understand it’s not FDA-approved, and who choose a program built on a licensed pharmacy and a real prescriber. If that’s you, Embody (sponsored affiliate link, opens in a new tab) offers compounded semaglutide and tirzepatide options with fast online onboarding and direct-to-door shipping, if treatment is appropriate for you. Before you commit to any compounded program, confirm its current medication type, the pharmacy it uses, which states it serves, and its cancellation terms.

Should you wait for VK2735 — or start an approved alternative now?

Don’t wait for VK2735 just because a headline number looked good. It still needs more trials and a full FDA review, and approval is never guaranteed. If you meet the medical criteria and a clinician agrees, FDA-approved options like Zepbound, Foundayo, and Wegovy are available routes today.

Start an approved option now if:

• You meet the BMI or weight-related-condition criteria and want a clinician-guided plan this year.
• You wanted VK2735 for its dual-hormone power — Zepbound gives you that, approved.
• You’d value help with insurance and prior authorization.
• You’d rather have an FDA-approved medicine than an experimental one.

Wait, or look into a trial, if:

• You specifically want VK2735 and you’re willing to go through clinical-trial screening — though the main Phase 3 VK2735 studies were already fully enrolled as of 2026, so check ClinicalTrials.gov for any newly recruiting study.
• You aren’t medically eligible for the approved options.
• Your clinician advises holding off.

The timeline math is the deciding factor for most people. Even on an optimistic path, VK2735 is roughly two years away. Two years is a long time to wait for a result you can start working toward this month.

VK2735 vs the other hyped peptides (retatrutide, CagriSema, MariTide)

Retatrutide, CagriSema, and MariTide come up in the same searches as VK2735 — but they’re the same dead end: all are investigational and not available by prescription for weight loss today. They’re worth watching, not chasing.

• Retatrutide (Eli Lilly): a triple agonist — it adds glucagon on top of GLP-1 and GIP. In its Phase 3 TRIUMPH-1 trial (reported in 2026), the top dose produced about 28.3% average weight loss at 80 weeks. Strong data — but not approved, with an FDA filing still ahead. Watchlist only. (See our retatrutide alternatives guide.)
• CagriSema (Novo Nordisk): combines semaglutide with an amylin drug, posted about 22.7% average weight loss at 68 weeks in its REDEFINE program. Novo filed it with the FDA in late 2025, but it’s not approved yet. Watchlist only.
• MariTide (Amgen): an experimental once-monthly injection with encouraging Phase 2 data. Still in trials, not approved. Watchlist only. (See our MariTide alternatives guide.)

Same rule applies to all three as to VK2735: if you want results now, the approved GLP-1 and dual-agonist medicines above are the only legitimate path.

Where to check eligibility for a VK2735 alternative

For FDA-approved alternatives, start with Ro if you want insurance help, prior-authorization support, and brand access in one place. Use Sesame as a strong second option if you want to compare provider choices and self-pay prices directly.

Ro — the best first step here

We’re routing you to Ro (sponsored affiliate link, opens in a new tab) first for a specific reason: this search resolves into FDA-approved, brand-name options, and Ro carries the two that matter most for VK2735 seekers — Zepbound (tirzepatide) and Foundayo (orforglipron) — with medication priced separately from membership. Ro matches the manufacturers’ direct (LillyDirect / NovoCare) medication pricing, offers a free GLP-1 Insurance Coverage Checker, and provides insurance-concierge support for patients whose plans require prior authorization. The membership: get started for $39, then as low as $74/month with the annual plan paid upfront (medication priced separately; confirm current terms before you sign up).

Sesame — the best second option for comparison shoppers

If you’d rather compare provider choices and see self-pay medication prices laid out, Sesame (sponsored affiliate link, opens in a new tab) is the move. Its weight-loss program shows cash-pay medication cards — including the Wegovy pill, Wegovy pen, Zepbound KwikPen, and Foundayo — with medication priced separately from the program fee.

How we ranked these VK2735 alternatives

We ranked by what’s useful to a patient, not by hype. Availability and FDA status come first, then how closely the drug matches VK2735’s mechanism, then the strength of the evidence, then price transparency, route (pill vs shot), and how legally clear it is. Any commission a provider pays us only breaks a tie after the evidence and your fit are equal — it never moves a worse option above a better one.

Here’s the exact rubric, scored out of 100:

Zepbound loses a couple of points only on route (it’s a shot) and price (higher than the pills), but it wins everywhere else. Foundayo gives back points on mechanism match (GLP-1 only, not dual) but tops the chart on route. Compounded GLP-1 scores well on mechanism and price but loses real ground on FDA status and legal clarity. The investigational drugs score low for one reason: you can’t get them.

What we actually verified for this page

We separate three kinds of claims: regulatory facts checked against the FDA and the drug makers; commercial facts checked directly on the manufacturers’ and providers’ own pages on the date below; and editorial judgments clearly labeled as our conclusions from those verified facts.

Drug prices and the compounding rules are the fastest-changing things on this page. We re-verify them monthly and update the date at the top. If you’re reading this well after that date, double-check the current numbers on each provider’s site before you decide.

Frequently asked questions

The bottom line

VK2735 looks powerful, but you can’t buy it — and you shouldn’t buy the knockoffs sold online. The closest thing you can actually get is Zepbound (tirzepatide) (sponsored affiliate link, opens in a new tab), which works on the same two hormones and is FDA-approved today. Want a pill instead of a shot? Foundayo or the Wegovy pill are your best FDA-approved options. And if cost is the real issue, there’s a lower-cost compounded route — just go in knowing the tradeoffs.

You came here ready to do something about your weight. The good news is you don’t have to wait two years or gamble on a gray-market vial to start. There’s a legal, regulated, evidence-backed path — and a clinician on the other side of it to decide whether it’s right for you.

Sources

• Viking Therapeutics — VK2735 mechanism, VANQUISH-1/VANQUISH-2 enrollment and Phase 3 status, oral VK2735 development (investor relations & SEC filings: ir.vikingtherapeutics.com; sec.gov)
• Obesity (The Obesity Society / Wiley) — peer-reviewed Phase 2 VENTURE results for subcutaneous VK2735 (2026)
• ClinicalTrials.gov — VK2735 (VANQUISH) Phase 3 listings
• U.S. Food & Drug Administration — Zepbound approval; Foundayo (orforglipron) approval (April 1, 2026); Wegovy HD approval (March 19, 2026); “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”; GLP-1 compounding policy updates
• Eli Lilly — Foundayo approval and pricing; Zepbound self-pay pricing via LillyDirect; retatrutide TRIUMPH-1 results
• Novo Nordisk / NovoCare — Wegovy pill (OASIS 4) and Wegovy HD (STEP UP) approvals and pricing; CagriSema FDA filing
• Ro — weight-loss program pricing, FDA-approved GLP-1 access, and GLP-1 Insurance Coverage Checker (June 16, 2026)
• Sesame Care — online weight-loss program pricing (June 16, 2026)
• Embody — compounded tirzepatide and semaglutide onboarding terms (June 16, 2026)

Prices, availability, and regulatory status change often. We re-verify pricing and FDA status monthly and update the “Last verified” date with each check.

Also see: VK2735 drug overview • Zepbound vs Wegovy • Best GLP-1 online programs • Retatrutide alternatives • MariTide alternatives